Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Aytu Biopharma (AYTU) Income towards Parent Company (2016 - 2025)

Aytu Biopharma has reported Income towards Parent Company over the past 15 years, most recently at $62000.0 for Q2 2025.

  • Quarterly Income towards Parent Company rose 105.0% to $62000.0 in Q2 2025 from the year-ago period, while the trailing twelve-month figure was $116000.0 through Dec 2025, up 108.7% year-over-year, with the annual reading at $620000.0 for FY2025, 118.65% up from the prior year.
  • Income towards Parent Company was $62000.0 for Q2 2025 at Aytu Biopharma, up from $54000.0 in the prior quarter.
  • Over five years, Income towards Parent Company peaked at $381000.0 in Q3 2024 and troughed at -$53.3 million in Q1 2022.
  • The 5-year median for Income towards Parent Company is -$1.2 million (2024), against an average of -$8.7 million.
  • Year-over-year, Income towards Parent Company crashed 546.8% in 2021 and then surged 158.89% in 2024.
  • A 5-year view of Income towards Parent Company shows it stood at -$11.5 million in 2021, then soared by 42.04% to -$6.7 million in 2022, then skyrocketed by 87.46% to -$839000.0 in 2023, then surged by 114.66% to $123000.0 in 2024, then crashed by 49.59% to $62000.0 in 2025.
  • Per Business Quant, the three most recent readings for AYTU's Income towards Parent Company are $62000.0 (Q2 2025), $54000.0 (Q1 2025), and $123000.0 (Q4 2024).